2,914 material Form 8-K filings that 2,352 companies we cover made with the SEC in August 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Nuwellis furnished an updated corporate presentation dated August 25, 2026, under Regulation FD, for use in investor communications and conferences. The deck highlights 20% first-half 2026 revenue growth and a second-quarter 2026 gross margin of 76%, compared with 56% in the prior-year period, and says cash runway extends through the second quarter of 2027.
First-half 2026 revenue grew 20% over the prior-year period, per the presentation.
Second-quarter 2026 gross margin was 76%, versus 56% in the prior-year period.
The company says cash runway runs through the second quarter of 2027.
Company anticipates an FDA submission for the Aquadex pediatric label expansion by year-end 2026.
Donaldson reported record fourth-quarter fiscal 2026 sales of $1.1 billion, up 8.0%, and GAAP diluted EPS of $1.10, up 13.4%. For fiscal 2027 it forecasts sales growth of 5.5% to 9.5% and EPS of $4.22 to $4.38, compared with fiscal 2026 GAAP EPS of $3.85, reflecting dilution from the Facet acquisition.
Q4 fiscal 2026 sales $1,058.8 million, up 8.0%; GAAP diluted EPS $1.10 versus $0.97; adjusted EPS $1.15 versus $1.03
Full-year fiscal 2026 sales $3.9 billion, up 5.3%; GAAP EPS $3.85, up 26.2%; adjusted EPS $3.98, up 8.2%
Fiscal 2027 guidance: EPS $4.22 to $4.38, including about $0.12 of dilution from Facet; operating margin 16.6% to 17.2%
Full-year fiscal 2026 cash used in acquisitions was $822.6 million, and long-term debt rose to $1,280.0 million from $630.4 million
HEICO reported record third-quarter fiscal 2026 results for the three months ended July 31, 2026. Net income rose 33% to $235.4 million, or $1.67 per diluted share, from $1.26 a year earlier, while net sales rose 23% to a record $1,413.1 million. The company said it expects increased net sales at both segments for the rest of fiscal 2026, but the filing gives no numeric guidance.
Q3 net income $235.4 million, or $1.67 per diluted share, versus $1.26 in Q3 fiscal 2025
Q3 net sales $1,413.1 million, up 23%, including 14% consolidated organic growth
Operating margin improved to 25.1% from 23.1%; operating cash flow rose 49% to $345.3 million
Issued $550 million 4.950% senior notes due 2031 and $650 million 5.400% senior notes due 2036, using proceeds to repay revolver borrowings
On August 25, 2026, Huntsman stockholders voted to adopt the Merger Agreement with Olin Corporation, with 131,502,454 votes for and 1,828,828 against. The companies will implement the combination as a direct merger, and the transaction is expected to close in the first half of 2027, subject to regulatory approvals and other closing conditions.
Merger proposal: 131,502,454 for, 1,828,828 against, 378,859 abstentions
Advisory vote on merger-related executive pay: 117,592,172 for, 15,456,713 against, 661,256 abstentions
Quorum of 133,710,141 votes, or 76.23% of the 175,381,417 shares entitled to vote as of the July 9, 2026 record date
Expected closing in the first half of 2027, subject to required regulatory approvals
nCino reported second-quarter fiscal 2027 results for the period ended July 31, 2026, with total revenues up 8% and GAAP operating income of $13.6 million, compared with a $9.3 million loss a year earlier. The board also authorized an additional $100 million stock repurchase program, and the company issued revenue and profit guidance for the third quarter and fiscal 2027.
Total revenues were $161.0 million, up 8% from $148.8 million; subscription revenues were $143.5 million, up 10%.
GAAP income from operations was $13.6 million versus a $9.3 million loss in the prior-year quarter; non-GAAP operating income was $40.8 million, up 36%.
The board authorized a new repurchase program of up to $100 million of common stock, following $300 million in repurchases since April 2025.
Third-quarter total revenues are guided to $161.25 million to $163.25 million; fiscal 2027 total revenues are guided to $644.0 million to $647.0 million.
Box reported second-quarter fiscal 2027 revenue of $321.1 million, up 9% from a year earlier, with GAAP diluted earnings per share of $0.09 versus $0.05 and non-GAAP diluted EPS of $0.40 versus $0.33. The company guided to third-quarter revenue of about $329 million and full-year fiscal 2027 non-GAAP EPS of about $1.54, and it repurchased 2.6 million shares for about $66 million in the quarter.
Revenue of $321.1 million, up 9%, or 11% in constant currency
GAAP diluted EPS of $0.09 vs. $0.05; non-GAAP diluted EPS of $0.40 vs. $0.33
Q3 fiscal 2027 revenue guidance of about $329 million; full-year revenue guidance of about $1.290 billion
Repurchased 2.6 million shares for about $66 million; about $378 million of buyback capacity remained as of July 31, 2026
Semtech reported second-quarter fiscal 2027 results for the quarter ended July 26, 2026, with net sales of $341.9 million, up 33% from a year earlier and up 17% from the prior quarter. GAAP net income was $160.1 million, which included a $101.4 million income tax benefit, compared with a net loss of $27.1 million a year earlier. The company also guided third-quarter net sales to $410.0 million plus or minus $5.0 million and adjusted diluted EPS to $1.05 plus or minus $0.03.
Net sales of $341.9 million, up from $257.6 million in Q2 FY2026 and $291.0 million in Q1 FY2027.
GAAP diluted EPS of $1.59, compared with a loss of $0.31 a year earlier; the quarter included a $101.4 million tax benefit.
Non-GAAP adjusted diluted EPS of $0.71, up from $0.41 in Q2 FY2026.
Q3 FY2027 outlook: net sales of $410.0 million plus or minus $5.0 million; adjusted diluted EPS of $1.05 plus or minus $0.03.
Zoom reported fiscal second-quarter 2027 results for the three months ended July 31, 2026. Revenue rose 4.9% to $1,277.2 million and non-GAAP diluted earnings per share rose to $1.55 from $1.53, while GAAP diluted EPS reached $5.15 mainly because of $1,614.2 million in gains on strategic investments. The company also updated its full fiscal 2027 outlook, which now calls for total revenue of $5.085 billion to $5.095 billion.
Total revenue $1,277.2 million, up 4.9%; Enterprise revenue $787.5 million, up 7.8%
GAAP net income $1,542.4 million ($5.15 per diluted share), versus $358.6 million ($1.16) a year earlier
GAAP income from operations $314.3 million, down from $321.7 million; free cash flow $472.4 million, down from $508.0 million
Full fiscal 2027 guidance: revenue $5.085 billion to $5.095 billion; non-GAAP diluted EPS $6.08 to $6.12
Manitowoc filed an 8-K furnishing an investor presentation for the Midwest IDEAS Investor Conference on August 26, 2026, which includes updated 2026 full-year guidance. The updated ranges are higher than prior guidance for net sales, adjusted EBITDA and adjusted diluted net loss per share, with adjusted EBITDA including a $16 million net benefit from tariff refunds.
Updated 2026 net sales guidance is $2.3 billion to $2.4 billion, up from $2.25 billion to $2.35 billion.
Updated adjusted EBITDA guidance is $150 million to $170 million, including a $16 million net benefit from tariff refunds, up from $125 million to $150 million.
Updated adjusted diluted net loss per share guidance is $0.80 to $1.20, up from $0.45 to $0.90.
The presentation is scheduled for Wednesday, August 26, 2026, at 12:15 PM ET, and the company states $29 million remains on its approved share repurchase plan.
Zymeworks announced that its partner Jazz Pharmaceuticals received FDA approval for two Ziihera regimens as first-line treatment of HER2-positive gastroesophageal adenocarcinoma. Zymeworks earned a $250 million milestone payment from Jazz on the approval and remains eligible for up to $1.3 billion in further milestones plus tiered royalties of 10% to 20% on Jazz's net sales. The filing does not report revenue, profit or guidance figures for the period.
FDA approved Ziihera plus tislelizumab and chemotherapy, and Ziihera plus chemotherapy, as first-line HER2+ GEA treatments, announced August 25, 2026
Zymeworks earned a $250 million milestone payment from Jazz; total payments from Jazz are $650 million to date
Zymeworks remains eligible for up to $1.3 billion in additional Jazz milestones and up to $144 million in BeOne milestones
Richtech Robotics said its board authorized repurchases of up to $12 million of Class B common stock, effective August 21, 2026, with the program running through August 21, 2027. The company said the program does not obligate it to buy any specific number of shares and may be changed or ended at any time, so the buyback's effect on shareholders depends on how much stock the company actually repurchases. The filing also reports a $750 per bi-weekly healthcare cash stipend for the CEO, CFO and COO.
Board authorized repurchases of up to $12 million of Class B common stock, effective August 21, 2026, through August 21, 2027
Repurchases to be made under a Rule 10b5-1 trading plan, subject to plan terms and market conditions
Company is not obligated to repurchase any specific number of shares; the board may modify, suspend or terminate the program without notice
Compensation committee approved a $750 healthcare cash stipend per bi-weekly paycheck for the CEO, CFO and COO, or about $19,500 annually in aggregate
Incannex Healthcare announced on August 25, 2026 that the first patient has been dosed in the DReAMzz Phase 2 dose-optimization study of IHL-42X, its oral drug candidate for obstructive sleep apnea. The company says the study is designed to inform dose selection for its planned Phase 3 program. The filing contains no financial results, guidance or funding figures.
First patient dosed in the DReAMzz Phase 2 study, announced August 25, 2026
All 14 DReAMzz sites have Institutional Review Board approval, and the study uses 14 clinical trial sites across the United States
Builds on prior Phase 2 RePOSA results showing statistically significant AHI reductions versus placebo, with individual reductions of up to 83%, and FDA Fast Track designation for IHL-42X
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.